Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival

뉴스 본문을 불러오고 있어요.

Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival | 웨이프 WAPE

Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival

기사 요약

관련 종목

댓글 —